在ICU患者的Ochrobactrum中间体引起的肺炎
Georgios Meletis1, Pinelopi Amoiridou2, Paraskevi Mantzana1
1Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece.
本报告详细介绍了第一个由Ochrobactrum intermedium引起的临床肺炎病例,这是一个罕见的机会性病原体. 这种感染发生在一名71岁的四肢男子身上,他因脊椎骨折住院.
科学领域:
- 医学微生物学 医学微生物学
- 临床传染病 临床传染病
- 肺部医学 肺部医学
背景情况:
- 奥克罗巴克特勒中间体是一种新兴的机会性病原体.
- 这种细菌主要与血液感染有关.
- 由O. intermedium引起的肺炎在临床环境中非常罕见.
研究的目的:
- 报告第一个被记录的由Ochrobactrum intermedium引起的肺炎临床病例.
- 突出O. intermedium可能导致呼吸道感染的潜力.
主要方法:
- 一个住院患者的病例报告.
- 临床数据收集和分析.
- 通过微生物学方法识别致病原体.
主要成果:
- 一名71岁的四肢的男性患者患上了肺炎.
- 这种肺炎被归因于Ochrobactrum中间体感染.
- 这名患者因脊椎骨折而入院.
结论:
- 光谱中间体可以引起肺炎,扩大其已知的临床谱.
- 这一案例强调了在复杂患者病例中考虑罕见病原体的重要性.
- 可能需要进一步的研究来了解O. intermedium肺炎的发病和治疗.
更多相关视频
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
相关概念视频
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Acute Respiratory Failure-III
